Bengaluru, India and Iselin, NJ, USA. October 4, 2021.
Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company today announced the launch of Everolimus tablets, a generic version of Afinitor®, in the US.
Everolimus tablets have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet being a ‘day-1’ generic launch. Everolimus (Afinitor®) is a prescription medication that is used to treat certain types of cancers and tumours.
The commercial launch of Everolimus follows an US FDA approval in February 2021.
Siddharth Mittal, Chief Executive Officer & Managing Director, said, “The launch of Everolimus tablets is another important addition to our generics portfolio and underscores our commitment to bringing complex, vertically integrated and affordable generic formulations to the market expeditiously. We will continue our focus on innovation and enhancing capacities to launch new products that make affordable healthcare accessible to millions of patients the world over.”
The Everolimus launch is further assertion of Biocon’s strategy to focus on vertically integrated, complex Finished Dosage Formulations (FDF) in niche therapeutic areas, using in-house Active Pharmaceutical Ingredient (API) capabilities.
According to IQVIA, US sales of Everolimus (Afinitor®) tablets of 2.5mg, 5mg, 7.5mg, and 10mg strengths were approximately $675 million in the 12 months ending July 2021.
Afinitor® is a registered trademark of Novartis AG.
About Biocon Limited: Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. www.biocon.com